We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Epredia - The PHC Group

Epredia, established in July 2019 through an acquisition by PHC Group from Thermo Fisher Scientific, is a global prec... read more Featured Products: More products

Download Mobile App




Standardized Staining Technology Advances Digital Pathology Workflows

By LabMedica International staff writers
Posted on 07 Aug 2026

Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools. More...

Laboratories require consistent, reproducible color and contrast to support remote review and algorithm performance at scale. A new quality-control slide system now supports standardized staining to accelerate AI-enabled diagnostic workflows.

The technology, called TANGO, was developed at Leeds Teaching Hospitals NHS Trust’s National Pathology Imaging Co-operative and is positioned for international deployment through a commercial agreement with Epredia. Under the partnership, Epredia will develop new pathology slide products incorporating TANGO and make them broadly accessible to laboratories adopting digital pathology. The agreement enables wider roll-out across the National Health Service (NHS) in the United Kingdom and internationally.

TANGO uses a specially designed reference slide that functions as a quality control measure during staining. By providing an internal standard within the staining workflow, the system is intended to reduce variation, improve inter-run consistency, and support faster, more efficient cancer diagnostics. The approach targets a widespread challenge in pathology labs where slight staining differences can affect result interpretation and limit the effectiveness of artificial intelligence tools.

According to the organizations, TANGO has been evaluated through international research demonstrating support for quality assurance across pathology workflows. Epredia, described as the world’s largest diagnostic glass slide manufacturer, plans to begin integrating TANGO into new laboratory slides from late 2026. The collaboration brings together NHS innovation and industry manufacturing expertise to extend access to standardized staining for digital and AI-enabled pathology.

“Digital pathology and AI have the potential to help accelerate cancer diagnostics speed and quality and ultimately improve patient care. By adding this powerful innovation to our world-class portfolio of precision cancer diagnostics products, we are investing in technologies that can help make that future a reality,” said Steven Lynum, President and CEO at Epredia.

Related Links
Leeds Teaching Hospitals NHS Trust
Epredia


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer

Assessing early benefit from immunotherapy in advanced non-small cell lung cancer can be challenging because radiographic responses may take months to become clear. Early scans can also be difficult to... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.